Inhibition of glutamine metabolism accelerates resolution of acute lung injury

Christine L. Vigeland, Henry S. Beggs, Samuel Lester Collins, Yee Chan-Li, Jonathan Powell, Claire M. Doerschuk, Maureen Horton

Research output: Contribution to journalArticle

Abstract

Despite recent advances, acute respiratory distress syndrome (ARDS) remains a severe and often fatal disease for which there is no therapy able to reduce the underlying excessive lung inflammation or enhance resolution of injury. Metabolic programming plays a critical role in regulating inflammatory responses. Due to their high metabolic needs, neutrophils, macrophages, and lymphocytes rely upon glutamine metabolism to support activation and function. Additionally, during times of physiologic stress, nearly all cells, including fibroblasts and epithelial cells, require glutamine metabolism. We hypothesized that inhibiting glutamine metabolism reduces lung inflammation and promotes resolution of acute lung injury. Lung injury was induced by instilling lipopolysaccharide (LPS) intratracheally. To inhibit glutamine metabolism, we administered a glutamine analogue, 6-diazo-5-oxo-L-norleucine (DON) that binds to glutamine-utilizing enzymes and transporters, after injury was well established. Treatment with DON led to less lung injury, fewer lung neutrophils, lung inflammatory and interstitial macrophages, and lower levels of proinflammatory cytokines and chemokines at 5 and/or 7 days after injury. Additionally, DON led to earlier expression of the growth factor amphiregulin and more rapid recovery of LPS-induced weight loss. Thus, DON reduced lung inflammation and promoted resolution of injury. These data contribute to our understanding of how glutamine metabolism regulates lung inflammation and repair, and identifies a novel target for future therapies for ARDS and other inflammatory lung diseases.

Original languageEnglish (US)
Article numbere14019
JournalPhysiological Reports
Volume7
Issue number5
DOIs
StatePublished - Mar 1 2019

Fingerprint

Acute Lung Injury
Glutamine
Norleucine
Pneumonia
Adult Respiratory Distress Syndrome
Wounds and Injuries
Lung Injury
Lipopolysaccharides
Diazooxonorleucine
Neutrophils
Macrophages
Lung
Chemokines
Lung Diseases
Weight Loss
Intercellular Signaling Peptides and Proteins
Fibroblasts
Epithelial Cells
Lymphocytes
Cytokines

Keywords

  • Acute lung injury
  • amphiregulin
  • glutamine
  • inflammation
  • resolution of injury

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Inhibition of glutamine metabolism accelerates resolution of acute lung injury. / Vigeland, Christine L.; Beggs, Henry S.; Collins, Samuel Lester; Chan-Li, Yee; Powell, Jonathan; Doerschuk, Claire M.; Horton, Maureen.

In: Physiological Reports, Vol. 7, No. 5, e14019, 01.03.2019.

Research output: Contribution to journalArticle

Vigeland, Christine L. ; Beggs, Henry S. ; Collins, Samuel Lester ; Chan-Li, Yee ; Powell, Jonathan ; Doerschuk, Claire M. ; Horton, Maureen. / Inhibition of glutamine metabolism accelerates resolution of acute lung injury. In: Physiological Reports. 2019 ; Vol. 7, No. 5.
@article{92e2fc07d6fc4c33a0ded45bdb0a372a,
title = "Inhibition of glutamine metabolism accelerates resolution of acute lung injury",
abstract = "Despite recent advances, acute respiratory distress syndrome (ARDS) remains a severe and often fatal disease for which there is no therapy able to reduce the underlying excessive lung inflammation or enhance resolution of injury. Metabolic programming plays a critical role in regulating inflammatory responses. Due to their high metabolic needs, neutrophils, macrophages, and lymphocytes rely upon glutamine metabolism to support activation and function. Additionally, during times of physiologic stress, nearly all cells, including fibroblasts and epithelial cells, require glutamine metabolism. We hypothesized that inhibiting glutamine metabolism reduces lung inflammation and promotes resolution of acute lung injury. Lung injury was induced by instilling lipopolysaccharide (LPS) intratracheally. To inhibit glutamine metabolism, we administered a glutamine analogue, 6-diazo-5-oxo-L-norleucine (DON) that binds to glutamine-utilizing enzymes and transporters, after injury was well established. Treatment with DON led to less lung injury, fewer lung neutrophils, lung inflammatory and interstitial macrophages, and lower levels of proinflammatory cytokines and chemokines at 5 and/or 7 days after injury. Additionally, DON led to earlier expression of the growth factor amphiregulin and more rapid recovery of LPS-induced weight loss. Thus, DON reduced lung inflammation and promoted resolution of injury. These data contribute to our understanding of how glutamine metabolism regulates lung inflammation and repair, and identifies a novel target for future therapies for ARDS and other inflammatory lung diseases.",
keywords = "Acute lung injury, amphiregulin, glutamine, inflammation, resolution of injury",
author = "Vigeland, {Christine L.} and Beggs, {Henry S.} and Collins, {Samuel Lester} and Yee Chan-Li and Jonathan Powell and Doerschuk, {Claire M.} and Maureen Horton",
year = "2019",
month = "3",
day = "1",
doi = "10.14814/phy2.14019",
language = "English (US)",
volume = "7",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Inhibition of glutamine metabolism accelerates resolution of acute lung injury

AU - Vigeland, Christine L.

AU - Beggs, Henry S.

AU - Collins, Samuel Lester

AU - Chan-Li, Yee

AU - Powell, Jonathan

AU - Doerschuk, Claire M.

AU - Horton, Maureen

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Despite recent advances, acute respiratory distress syndrome (ARDS) remains a severe and often fatal disease for which there is no therapy able to reduce the underlying excessive lung inflammation or enhance resolution of injury. Metabolic programming plays a critical role in regulating inflammatory responses. Due to their high metabolic needs, neutrophils, macrophages, and lymphocytes rely upon glutamine metabolism to support activation and function. Additionally, during times of physiologic stress, nearly all cells, including fibroblasts and epithelial cells, require glutamine metabolism. We hypothesized that inhibiting glutamine metabolism reduces lung inflammation and promotes resolution of acute lung injury. Lung injury was induced by instilling lipopolysaccharide (LPS) intratracheally. To inhibit glutamine metabolism, we administered a glutamine analogue, 6-diazo-5-oxo-L-norleucine (DON) that binds to glutamine-utilizing enzymes and transporters, after injury was well established. Treatment with DON led to less lung injury, fewer lung neutrophils, lung inflammatory and interstitial macrophages, and lower levels of proinflammatory cytokines and chemokines at 5 and/or 7 days after injury. Additionally, DON led to earlier expression of the growth factor amphiregulin and more rapid recovery of LPS-induced weight loss. Thus, DON reduced lung inflammation and promoted resolution of injury. These data contribute to our understanding of how glutamine metabolism regulates lung inflammation and repair, and identifies a novel target for future therapies for ARDS and other inflammatory lung diseases.

AB - Despite recent advances, acute respiratory distress syndrome (ARDS) remains a severe and often fatal disease for which there is no therapy able to reduce the underlying excessive lung inflammation or enhance resolution of injury. Metabolic programming plays a critical role in regulating inflammatory responses. Due to their high metabolic needs, neutrophils, macrophages, and lymphocytes rely upon glutamine metabolism to support activation and function. Additionally, during times of physiologic stress, nearly all cells, including fibroblasts and epithelial cells, require glutamine metabolism. We hypothesized that inhibiting glutamine metabolism reduces lung inflammation and promotes resolution of acute lung injury. Lung injury was induced by instilling lipopolysaccharide (LPS) intratracheally. To inhibit glutamine metabolism, we administered a glutamine analogue, 6-diazo-5-oxo-L-norleucine (DON) that binds to glutamine-utilizing enzymes and transporters, after injury was well established. Treatment with DON led to less lung injury, fewer lung neutrophils, lung inflammatory and interstitial macrophages, and lower levels of proinflammatory cytokines and chemokines at 5 and/or 7 days after injury. Additionally, DON led to earlier expression of the growth factor amphiregulin and more rapid recovery of LPS-induced weight loss. Thus, DON reduced lung inflammation and promoted resolution of injury. These data contribute to our understanding of how glutamine metabolism regulates lung inflammation and repair, and identifies a novel target for future therapies for ARDS and other inflammatory lung diseases.

KW - Acute lung injury

KW - amphiregulin

KW - glutamine

KW - inflammation

KW - resolution of injury

UR - http://www.scopus.com/inward/record.url?scp=85062982200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062982200&partnerID=8YFLogxK

U2 - 10.14814/phy2.14019

DO - 10.14814/phy2.14019

M3 - Article

VL - 7

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 5

M1 - e14019

ER -